08:00 , Dec 21, 2015 |  BC Week In Review  |  Company News

Pharmsynthez, Kevelt, Xenetic deal

Xenetic will purchase worldwide rights to develop and commercialize Virexxa from Kevelt and Pharmsynthez for 111.5 million shares of Xenetic, valued at $93.7 million based on Xenetic close of $0.84 on Nov. 13, the last...
08:00 , Jan 17, 2005 |  BC Week In Review  |  Company News

CeMines deal

CeMines and several parties co-founded VTAK, which is focused on cancer diagnostics therapeutics. VTAK was founded by CeMines' CeMines Estonia OU subsidiary, Tallinn Technical University, Helsinki Yliopiston Saatio, Regional Hospital of North Estonia, ProSyntest AS,...